Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis

BACKGROUND: Vulvovaginal candidiasis affects approximately 75% of women in their lifetime. Approved treatment options are limited to oral or topical azoles. Ibrexafungerp, a novel, first-in-class oral triterpenoid glucan synthase inhibitor, has demonstrated broad fungicidal Candida activity and a fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyirjesy, Paul, Schwebke, Jane R, Angulo, David A, Harriott, Itzel A, Azie, Nkechi E, Sobel, Jack D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258939/
https://www.ncbi.nlm.nih.gov/pubmed/34555149
http://dx.doi.org/10.1093/cid/ciab841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258939/
https://www.ncbi.nlm.nih.gov/pubmed/34555149
http://dx.doi.org/10.1093/cid/ciab841

Ejemplares similares